Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway by Zhu, Yanping et al.
Pharmacological Inhibition of O‑GlcNAcase Enhances Autophagy in
Brain through an mTOR-Independent Pathway
Yanping Zhu,†,‡,§ Xiaoyang Shan,† Farzaneh Safarpour,§,∥ Nancy Erro Go,⊥ Nancy Li,‡ Alice Shan,†
Mina C. Huang,§,∥ Matthew Deen,† Viktor Holicek,† Roger Ashmus,† Zarina Madden,†
Sharon Gorski,‡,§,⊥ Michael A. Silverman,§,∥ and David J. Vocadlo*,†,‡,§
†Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
‡Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
§Centre for Cell Biology, Development, and Disease, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
∥Department of Biological Sciences, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
⊥The Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada
ABSTRACT: The glycosylation of nucleocytoplasmic pro-
teins with O-linked N-acetylglucosamine residues (O-GlcNAc)
is conserved among metazoans and is particularly abundant
within brain. O-GlcNAc is involved in diverse cellular
processes ranging from the regulation of gene expression to
stress response. Moreover, O-GlcNAc is implicated in various
diseases including cancers, diabetes, cardiac dysfunction, and
neurodegenerative diseases. Pharmacological inhibition of O-
GlcNAcase (OGA), the sole enzyme that removes O-GlcNAc,
reproducibly slows neurodegeneration in various Alzheimer’s
disease (AD) mouse models manifesting either tau or amyloid
pathology. These data have stimulated interest in the
possibility of using OGA-selective inhibitors as pharmaceuticals to alter the progression of AD. The mechanisms mediating
the neuroprotective effects of OGA inhibitors, however, remain poorly understood. Here we show, using a range of methods in
neuroblastoma N2a cells, in primary rat neurons, and in mouse brain, that selective OGA inhibitors stimulate autophagy through
an mTOR-independent pathway without obvious toxicity. Additionally, OGA inhibition significantly decreased the levels of toxic
protein species associated with AD pathogenesis in the JNPL3 tauopathy mouse model as well as the 3×Tg-AD mouse model.
These results strongly suggest that OGA inhibitors act within brain through a mechanism involving enhancement of autophagy,
which aids the brain in combatting the accumulation of toxic protein species. Our study supports OGA inhibition being a feasible
therapeutic strategy for hindering the progression of AD and other neurodegenerative diseases. Moreover, these data suggest
more targeted strategies to stimulate autophagy in an mTOR-independent manner may be found within the O-GlcNAc pathway.
These findings should aid the advancement of OGA inhibitors within the clinic.
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■ INTRODUCTION
The rising incidence of Alzheimer’s disease (AD) within the
aging population is causing increased social and economic
burden. Because no disease modifying therapies are yet
available, there is great interest in understanding both the
basic biological mechanisms contributing to AD as well as
advancing possible therapeutic approaches to slow or stop the
progression of AD. The two well established pathological
hallmarks of the disease are the neurofibrillary tangles (NFTs)
and amyloid plaques that form within the brain. NFTs are
composed of paired helical filaments (PHFs) of the cytoskeletal
protein tau,1 whereas amyloid plaques stem from aggregation of
a proteolytic fragment of the amyloid precursor protein
(APP).2,3 There is growing consensus that amyloid initiates
the AD cascade while pathological tau species, such as tau
oligomers, drive neuronal death.4,5 The central role of tau is
supported by the close correlation between tau pathology and
neuronal degeneration as well as clinical progression of the
disease.6,7 Consistent with this view, mutations in tau have been
directly linked to neurodegenerative diseases.8,9 Notably, tau is
subject to many post-translational modifications (PTMs),10,11 a
number of which are involved in its pathological oligomeriza-
tion and subsequent assembly into PHFs and NFTs.10−12
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Both tau13−16 and APP17 are modified with an intracellular
form of glycosylation known as O-linked N-acetylglucosamine
(O-GlcNAc). O-GlcNAc is a dynamic protein modification
found on nuclear, cytoplasmic, and mitochondrial proteins.18,19
Though found on hundreds of proteins, levels of this
modification are principally controlled by only two enzymes.18
O-GlcNAc is installed on the hydroxyl groups of specific serine
and threonine residues19 by the enzyme O-GlcNAc transferase
(OGT) using UDP-GlcNAc as a sugar donor,20 and its removal
is catalyzed by O-GlcNAcase (OGA).21 It has been proposed
that impaired brain glucose utilization within AD brain
diminishes O-GlcNAcylation and enables the formation of
toxic protein species.15 OGA inhibitors slow the removal of O-
GlcNAc from proteins while OGT continues to act, which leads
to decreased rates of turnover of O-GlcNAc on proteins and a
net increase in global protein O-GlcNAcylation. A series of
studies using OGA inhibitors to elevate global levels of O-
GlcNAc within various transgenic models of AD have shown
that such compounds can lower Aβ levels and plaque
burden,22,23 levels of pathological tau,24−27 protect against
neurodegeneration, and improve behavior without causing
apparent toxicity.22−28 These promising findings have driven
interest in using potent and selective OGA inhibitors as
potential disease-modifying therapeutics for AD and other
tauopathies, recently attracting attention from industry, which
has advanced compounds to the clinic.29
The mechanisms by which OGA inhibitors decrease Aβ and
tau pathologies and exert protective effects within the brain,
however, remain ill defined. As noted, tau has been found to be
O-GlcNAc modified13−16 and O-GlcNAcylated tau is less prone
to aggregation.24 OGA inhibitors may therefore act directly by
increasing tau glycosylation and hindering its downstream toxic
effects. Others, however, have proposed that tau is not O-
GlcNAc modified26 or that the fraction of tau modified in this
way is low.10 Moreover OGA inhibitors have beneficial effects
on behavior in tauopathy mouse models, even after short-term
treatment, which seem unlikely to stem only from blocking tau
toxicity and so suggest that mechanisms other than direct
modification of tau are operative.26 Accordingly, we were
motivated to consider potential mechanisms by which OGA
inhibitors might be able to protect against such proteotoxicity.
Macroautophagy, referred to here simply as autophagy, is the
process by which cytoplasmic constituents, including protein
aggregates and organelles, are sequestered in double-membrane
structures called autophagosomes and delivered to lysosomes
for degradation.30 Both Aβ and tau are now recognized as being
cleared in part by autophagy and impaired autophagy has
emerged as a feature of AD as well as other neurodegenerative
diseases.31 We were motivated by several reports showing that
remediating autophagic failure,32 or stimulating autophagic
clearance, correlates with reduced numbers of aggregates of Aβ
and tau and reduces neurodegeneration in AD mouse
models.33−36 Given the concordance in the effects on tau and
Aβ pathologies observed using known autophagy en-
chancers33−36 and OGA inhibitors,23,24 coupled with emerging
data using genetic methods that suggest the O-GlcNAc
pathway influences autophagy,37−40 we speculated that OGA
inhibitors might exert their protective effects in AD mouse
models by enhancing autophagy within brain.
To interrogate the potential protective mechanisms of OGA
inhibitors, we set out to test whether OGA inhibition stimulates
autophagic flux within brain. Here, we show that OGA
inhibitors act though an mTOR-independent manner to
enhance autophagosome formation and increased autophagic
flux both in vitro in immortal neuroblastoma cells and cultured
primary neurons and astrocytes, as well as in vivo in mouse
brain. We find that OGA inhibitors induced autophagy in two
AD mouse models and that this correlates with reduced levels
of pathological tau species. These results are consistent with the
view that OGA inhibitors mediate their protective effects in
AD, at least in part, by enhancing autophagy. Our findings here
suggest OGA inhibitors should be generally protective in
proteinopathy models in which induction of autophagy is
beneficial. Moreover, the mTOR-independent nature of these
effects is consistent with these compounds being well tolerated
in AD mouse models and may open the door to more targeted
strategies to induce autophagy within brain for therapeutic
benefit.
■ RESULTS AND DISCUSSION
Given the great potential of OGA inhibitors as disease
modifiers for treating tauopathies22−28 and the advance of
OGA inhibitors into the clinic,29 an improved understanding of
the processes by which OGA inhibitors affect cell physiology
and associated cellular processes that could help combat tau
toxicity are of great interest. Such knowledge should aid clinical
development of OGA inhibitors and could also help uncover
specific O-GlcNAcylated proteins that could be modulated in a
more targeted manner for therapeutic benefit. Given that
several papers have shown perturbations in O-GlcNAc levels
have divergent effects on autophagy in various peripheral
tissues37−40 and that various autophagy enhancers decrease
toxic tau species within tauopathy mouse models and provide
protective benefits,33−35,41,42 we set out to explore whether
OGA inhibitors might stimulate autophagy in mammalian
brain.
Inhibition of OGA Enhances Autophagy in Neuro-
blastoma Neuro-2a (N2a) Cells and Cultured Rat
Primary Neurons and Astrocytes. Microtubule-associated
protein 1 light chain 3 (LC3) is a ubiquitin-like modifier
involved in autophagosome biogenesis. During the process of
autophagy, pro-LC3 is processed to form LC3-I, which is
subsequently conjugated to phosphatidylethanolamine (PE) to
form LC3-II on the membrane of the phagophore where it
promotes autophagosome formation. Following fusion of
autophagosomes with lysosomes, intravacuolar LC3-II is
degraded. Accordingly, monitoring the formation and degrada-
tion of LC3-II is a useful and well established measure for
monitoring autophagy. Here, we selected the LC3B family
member as an autophagy marker because of its abundance
within brain43 and monitored formation of LC3B−II (LC3BII).
As a first step to explore whether inhibiting OGA influences
autophagy in neurons, we used Neuro-2a (N2a) neuroblastoma
cells as a convenient model system. We treated cells for 2 days
with different concentrations of the OGA inhibitor Thiamet-
G44 (TMG) ranging from 25 nM to 250 μM and found
increased levels of O-GlcNAc (Figure S1A). In the absence of
bafilomycin A1, which blocks fusion of autophagosomes with
lysosomes to form autolysosomes, we found no significant
difference in the levels of LC3BII among cells treated with
autophagy inducer rapamycin, different doses of TMG, and
vehicle alone. In the presence of bafilomycin A1, the lowest
does of TMG (25 nM) increased the level of LC3BII as
compared with control, although the difference was not
statistically significant (Figure S1B). Treatment with 100 nM
TMG led to modest but statistically significant increases in
LC3BII level as compared with vehicle alone, and this effect on
LC3BII levels was comparable to treatment with rapamycin
(Figure S1B). These data suggest that OGA inhibition by TMG
enhances autophagy within N2a cells. To address whether
longer term OGA inhibition can induce sustained levels of
autophagy, we next treated N2a cells with TMG for 15 days
with 250 nM or 100 μM Thiamet-G followed by inhibition of
autophagosome-lysosome fusion through the addition of
bafilomycin A1 for 4 h. This long-term treatment significantly
increased the levels of LC3BII as compared with vehicle alone
(Figure 1A and B) and these effects on the levels of LC3BII
were slightly greater than the shorter term 2-day dosing and
were again comparable to the effect of rapamycin (Figure 1A
and B). These data indicated that TMG could activate
autophagy in a sustained manner. To confirm these findings,
we used high-content cellular analysis to assess autophagic flux
in live N2a cells treated with either 250 nM or 100 μM TMG
using CYTO-ID (Enzo Life Sciences), which selectively stains
autophagosomes and enables their quantitation by fluorescence
imaging. CYTO-ID imaging revealed that rapamycin and TMG,
with either a short (2 days) or long (15 days) treatment
protocol, enhanced autophagy as compared to vehicle-treated
cells, this time using the autophagy inhibitor chloroquine (CQ).
These data are consistent with our immunoblot analyses of
LC3BII and reveal activation of autophagy by TMG at both
concentrations of 250 nM and 100 μM (Figure 1C and D). In
this experiment we again observed that long-term (15 day)
TMG treatment induced a higher level of autophagic flux than
short-term (2 day) treatment (Figure 1C and D). As a further
test, we exploited the established tandem reporter system based
Figure 1. Inhibition of OGA by Thiamet-G (TMG) enhances autophagic flux in neuroblastoma Neuro-2a (N2a) cells. (A) Immunoblot analysis of
levels of LC3BII in whole cell lysates from control and TMG-treated N2a cells. Con: vehicle control; Rapa: rapamycin, 2.5 μM for 4 h; TMG-S:
TMG, 100 μM for 2 days; TMG-L: TMG, 100 μM for 15 days; Baf: bafilomycin A1, 100 nM for 4 h. (B) Densitometry of immunoblot signals in (A)
was quantified using Odyssey software (Li-Cor). Values were normalized to corresponding beta-actin immunoblot signals, then normalized to
control (arbitrarily set as 1). Error bars represent ± SD. p-Values were derived from a one-way analysis of variance (ANOVA) comparing
immunoblot signals from each treatment to control, respectively. n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. Treatments without significant
differences were not labeled. (C) High-content cellular analysis of autophagic flux in live N2a cells using CYTO-ID Autophagy Detection Kit 2.0
(Enzo) which selectively labels autophagosomes. Con: vehicle control; Rapa: rapamycin, 2.5 μM for 4 h; TMG-S: TMG, 100 μM for 2 days; TMG-
L: TMG, 100 μM for 15 days; CQ: Chloroquine, 25 μM for 4 h. Fluorescent signals from CYTOID staining of cells was quantified with automated
methods using MetaXpress software (Molecular Devices). Error bars represent ± SD. p-Values were derived from a one-way analysis of variance
(ANOVA) comparing fluorescent intensity of CYTOID staining from each treatment to control, respectively. n = 3; *p < 0.05, **p < 0.01, ***p <
0.001. (D) Representative images of high-content cellular analysis in (C). (E) Evaluation of autophagic flux in live N2a cells stably expressing tandem
fluorescent protein pHluorin-mKate2-LC3 measured by high-content imaging (ImageXpress Micro XLS, Molecular Devices). Con: vehicle control;
Rapa: rapamycin, 2.5 μM for 4 h; TMG: Thiamet-G, 100 μM for 15 days; TMG+Rapa: TMG, 100 μM for 15 days and Rapa, 2.5 μM for 4 h. Red
and yellow puncta number per cell was automatically quantified using MetaXpress software. Error bars represent ± SD. p-Values were derived from a
one-way analysis of variance (ANOVA) comparing the ratio of red/yellow puncta number per cell from each treatment to control, respectively. n =
3; *p < 0.05, **p < 0.01, ***p < 0.001. (F) Representative images of high-content imaging analysis in (E).
on using the autophagy maker protein LC3 as a fusion with two
fluorescent proteins having orthogonal photophysical proper-
ties (pHluorin-mKate2-LC3)45 to generate an N2a cell line
stably expressing this system. We treated this cell line with 250
nM or 100 μM of TMG for 15 days and assessed the extent of
autophagic flux using high-content imaging analysis. Here too
we found that both 250 nM and 100 μM TMG significantly
increased autophagic flux presented as the ratio of red/yellow
puncta per cell as compared with control (Figure 1E and F),
with the increase being again comparable as seen when using
rapamycin. Notably, we also observed greater autophagic flux in
cells cotreated with both TMG and rapamycin as compared to
cells treated with either TMG or rapamycin only (Figure 1E
and F), suggesting these agents act through independent
pathways to yield an additive enhancement in autophagic flux.
To confirm that the enhancement of autophagy stems from
OGA inhibition rather than some potential off-target effect of
Thiamet-G, we tested two other structurally distinct OGA
inhibitors46 synthesized in-house at 250 nM. Both OGA
inhibitors activated autophagy to a similar extent as TMG
(Figure S2). These collective data support inhibition of OGA
enhancing autophagy in N2a cells.
We next set out to evaluate the effect of OGA inhibition on
autophagy in cultured rat primary neurons and astrocytes,
which are more physiologically relevant models. Again, in the
absence of bafilomycin, we observed no significant difference in
the levels of LC3BII among control, rapamycin, and TMG
treatments (3 day) as measured by immunoblot. However, after
blocking autophagy using bafilomycin, LC3BII level increased
significantly in the treatment with TMG (100 μM) as
compared to cells treated with vehicle alone (Figure 2A).
The effect of TMG on LC3BII was similar to that of the
autophagy enhancer rapamycin (Figure 2A), supporting OGA
inhibition induces autophagy in primary neurons. To confirm
the enhancement of autophagic flux by TMG using a separate
measure, we transiently transfected primary neurons with the
tandem fluorescent reporter pHluorin-mKate2-LC3, and
measured autophagic flux by fluorescence microscopy. We
found that TMG treatment significantly increased autophagic
flux shown as the ratio of red/yellow puncta number as
compared with control (Figure 2B). Similar to primary
neurons, we found that TMG treatment also raised the level
of LC3BII in rat primary astrocytes after blocking formation of
autolysosomes (Figure S3), suggesting induction of autophagy
by TMG in astrocytes. These data together indicate that
inhibition of OGA may promote autophagy within brain.
Inhibiting OGA Enhances Autophagic Flux in the
Brain of RFP-GFP-LC3 Autophagy Reporter Mice. To
address whether TMG influences autophagy within brain in
vivo, we used as a model system the transgenic mouse strain
CAG-RFP-EGFP-LC3 (C57BL/6-Tg(CAG-RFP/GFP/
Map1lc3b)1Hill/J), which constitutively expresses the autoph-
agy marker protein LC3 tagged with tandem fluorescent
proteins (RFP-EGFP-LC3).47 After the treatment of mice with
TMG (500 mg/kg/d) in drinking water for 2 weeks, we found
that the number of autophagosomes (yellow puncta) in the
cortex was comparable between control and treated mice,
whereas the number of autophagolysosome (red puncta)
significantly increased in treated mice compared over the
observed number in control mice (Figure 3A). TMG treatment
also significantly increased autophagic flux as measured by the
increased ratio of red/yellow puncta in treated mice as
compared to controls (Figure 3A). Similar results were
observed in other brain regions including brain stem and
hippocampus (data not shown). These observations indicated
that blocking OGA activity by TMG enhanced autophagic flux
within mouse brain. To consolidate these imaging data, we also
assessed the levels of Sequestosome-1 (SQSTM1), LC3BII and
Figure 2. OGA inhibition by Thiamet-G (TMG) promotes autophagic flux in cultured rat primary neurons. (A) Immunoblot analysis of levels of
LC3BII in whole cell lysates from control and TMG-treated primary cortical neurons. Con: vehicle control; Rapa: rapamycin, 0.2 μM for 72 h;
TMG: Thiamet-G, 100 μM for 72 h; Baf: bafilomycin A1, 100 nM for 4 h. Densitometry of immunoblot signals was quantified using Odyssey
software (Li-Cor). Values were normalized to corresponding beta-actin immunoblot signals, then normalized to control (arbitrarily set as 1). Error
bars represent ± SD. p-Values were derived from a one-way analysis of variance (ANOVA) comparing immunoblot signals from each treatment to
control, respectively. n = 3 independent cultures; *p < 0.05, **p < 0.01, ***p < 0.001. Treatments without significant differences were not labeled.
(B) Evaluation of autophagic flux in live primary hippocampal neurons transiently expressing tandem fluorescent protein pHluorin-mKate2-LC3
using fluorescence microscopy. Con: vehicle control; TMG: Thiamet-G, 100 μM for 72 h. Red and yellow puncta number per cell were quantified
using at least 20 cells per culture and per condition. Error bars represent ± SD. *p < 0.05 by unpaired Student’s t test (n = 3). Arrows denote
mKate2 (red) positive structures.
Figure 3. Increasing O-GlcNAc by using the selective OGA inhibitor Thiamet-G (TMG) enhances autophagic flux within brains of RFP-EGFP-LC3
mice. (A) Fluorescence analysis of the cortex region of sagittal sections from control and TMG-treated (500 mg/kg/d in drinking water for 2 weeks)
mice constitutively expressing the tandem fluorescent autophagy maker protein RFP-EGFP-LC3. Numbers of red (autolysosome) and yellow
(autophagosome) puncta were quantified using Nikon NIS-element software. Error bars represent ± SD. *p < 0.05 by unpaired Student’s t test (n =
7). Comparisons that were not significantly different are unlabeled. (B) Immunoblot analysis of levels of O-GlcNAc, SQSTM1, and endogenous
LC3I and LC3II in cortex lysate samples from control and TMG-treated RFP-EGFP-LC3 mice. Immunoblot signals were quantified using Odyssey
software (Li-Cor). Values of immunoblot signals were normalized to those of corresponding beta-actin signals. Error bars represent ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001 by unpaired Student’s t test (n = 7).
Figure 4. OGA inhibition by Thiamet-G (TMG) stimulates autophagy in AD mouse (JNPL3-Tau4R0NP301L) brain. Fluorescent
immunohistochemical analysis of the cortex region using sagittal sections from control and TMG-treated (500 mg/kg/d in drinking water for
36 weeks) JNPL3 mice as measured using anti-LC3 and anti-pathological tau (AT8) antibodies (A), or anti-SQSTM1 and anti-O-GlcNAc
(CTD110.6) antibodies (B). Immunofluorescence signals were quantified using Nikon NIS-element software. Error bars represent ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001 by unpaired Student’s t test (n = 7). (C) Immunoblot analysis of levels of O-GlcNAc, LC3BI, LC3BII, and SQSTM1 in
cortex lysate samples from control and TMG-treated JNPL3 mice. Immunoblot signals were quantified using Odyssey software (Li-Cor). Values of
immunoblot signals were normalized to those of corresponding beta-actin signals. Error bars represent ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by
unpaired Student’s t test (n = 7).
O-GlcNAc using immunoblotting. SQSTM1 is an autophagy
receptor, which can recognize and recruit specific cargoes for
autophagic degradation. SQSTM1 is degraded during the
process of autophagy and thus levels of SQSTM1 can serve,
when used in conjunction with other measures, as another
marker to aid in assessing autophagic flux. We found that OGA
inhibition significantly increased the levels of O-GlcNAc and
LC3BII, but decreased the level of SQSTM1 (Figure 3B).
These immunoblot data are consistent with the imaging data
described above and indicated that OGA inhibition by TMG
promoted autophagy in the brain.
Pharmacological Inhibition of OGA Enhances Au-
tophagy and Reduces Pathological Tau Species in
Alzheimer’s Disease Mouse Brain. Previous studies showed
that OGA inhibition protects against neurodegeneration in the
brain of various AD model mice.22−27 Given that our in vitro
and in vivo studies described above indicate inhibition of OGA
activates autophagy, and that previous studies have shown that
other methods that upregulate autophagic flux slow neuro-
degeneration,33−35,41,42 we speculated that the protective
function of TMG in tauopathy model mice might be mediated
by enhanced autophagy. In order to test this hypothesis, we
used JNPL3 tau transgenic mice that express mutant human tau
P30lL48 as a tauopathy model. Our previous study showed that
long-term (36 weeks) TMG treatment hindered the formation
of tau aggregates and decreases neuronal cell loss in JNPL3
mouse.24 Here, using the same mouse model and treatment
conditions24 (500 mg/kg/day of TMG in drinking water over
36 weeks), we assessed autophagy in the brain using
immunofluorescence. We observed that the number of LC3B
immunoreactive puncta increased, whereas the intensity of
SQSTM1 immunoreactivity in cortex was decreased in TMG-
treated mice as compared to control mice (Figure 4A). These
data are consistent with our observations made in RFP-EGFP-
LC3 mouse brain and support OGA inhibition inducing
persistent increases in autophagic flux within mouse brain. In
addition, we found that levels of pathological tau as detected by
AT-8 antibody decreased significantly, whereas O-GlcNAc
immunoreactivity was greatly increased within the cortex of
brains from TMG-treated mice (Figure 4A), which is in accord
with previous studies by us and others.24 We also observed
both enhanced autophagy and a reduction in the levels of
pathological tau, as measured using the AT-8 antibody, in other
brain regions including both brain stem and hippocampus in
TMG-treated mice (data not shown). These data together
collectively indicate that OGA inhibition by TMG enhanced
autophagic flux in mouse brain, and may contribute to clearing
pathological tau species and thereby protecting against its
Figure 5. Thiamet-G (TMG) enhances autophagy through an mTOR-independent pathway. (A) TMG treatment did not alter the activity of mTOR
in the brains of JNPL3 mice treated with TMG for 36 weeks. Immunoblot analysis of levels of total and phosphorylated epitopes of mTOR and
p70S6K in cortex lysate samples from control and TMG-treated JNPL3 mice. Immunoblot signals were quantified using Odyssey software (Li-Cor).
The ratio between the corresponding phosphorylated epitope and total protein was determined. Error bars represent ± SD. *p < 0.05, **p < 0.01,
***p < 0.001 by unpaired Student’s t test (n = 7). Comparison not showing significant differences are unlabeled. (B) Immunoblot analysis of levels
of total and phosphorylated epitopes of mTOR and 4EBP1 in rat primary cortical neurons. Con: vehicle control; Rapa: rapamycin, 0.2 μM for 72 h;
TMG: Thiamet-G, 100 μM for 72 h. The ratio between the corresponding phosphorylated epitope and total protein was determined, and then
normalized to control (arbitrarily set as 1). Error bars represent ± SD. p-Values were derived from a one-way analysis of variance (ANOVA). n = 3;
*p < 0.05, **p < 0.01, ***p < 0.001. (C) Immunoblot analysis of levels of total and phosphorylated epitopes of p70S6K and 4EBP1 in N2a cells.
Rapa: rapamycin, 2.5 μM for 4 h; TMG-S: TMG, 100 μM for 2 days; TMG-L: TMG, 100 μM for 15 days. The ratio between the corresponding
phosphorylated epitope and total protein was determined, and then normalized to control (arbitrarily set as 1). Error bars represent ± SD. p-Values
were derived from a one-way analysis of variance (ANOVA). n = 3; *p < 0.05, **p < 0.01, ***p < 0.001.
spread. In order to draw comparison with our studies described
above, we measured the levels of O-GlcNAc, and the levels of
standard autophagy markers including LC3BI, LC3BII, and
SQSTM1 by immunoblot. All except SQSTM1 showed
increased levels in TMG treated mice as compared to those
treated with vehicle alone (Figure 4B). These immunoblot
results are consistent with the immunofluorescence data in the
JNPL3 mice as well as the RFP-EGFP-LC3 tandem reporter
mice.
To evaluate the effects of shorter term dosing of TMG on
autophagy in brain and confirm OGA inhibition influences
autophagy in another AD model, we opted to use the 3×Tg-AD
which harbors human tau (P301L), APP (KM670/671NL) and
PS1 (M146V) mutant transgenes.49 We treated these mice with
either TMG (500 mg/kg/day) or vehicle alone in drinking
water, as before but for only 2 weeks, and then assessed
autophagy in the mouse brain using immunofluorescence. We
found that both the number of LC3 puncta and SQSTM1
immunoreactivity were significantly reduced in cortex regions
of TMG-treated mice as compared with control mice (Figure
S4A). Notably, we also found that OGA inhibition with TMG
reduced the levels of pathological tau as detected using the AT-
8 antibody, whereas O-GlcNAc immunoreactivity was greatly
increased in cortex (Figure S4A). Similar alterations in the
number of LC3 puncta, levels of SQSTM1, and pathological tau
were observed in other brain regions of TMG-treated mice
including brain stem and hippocampus (data not shown).
Unlike in JNPL3 mouse, however, we found that this shorter
term OGA inhibition decreased the number of LC3 puncta in
3×Tg-AD as compared to control mice, yet the level of
SQSTM1 was significantly reduced after TMG treatment to a
similar extent as we had observed in the JNPL3 mice. This
difference may be attributable to more robust autophagic flux
including faster fusion between autophagosomes and lysosomes
as well as higher lysosomal degradation capacity in the brains of
these 3×Tg-AD mice, though this remains speculative.
Nevertheless, these data support the view that OGA inhibition
by TMG enhanced autophagy in the brain of these 3×Tg AD
model mouse, which may be a factor driving the clearance of
toxic tau species. Again, to use a separate method, we
performed immunoblot analyses and found that levels of O-
GlcNAc were significantly increased, whereas the levels of
LC3BII, LC3BI and SQSTM1 were all decreased in the brain of
mice treated with TMG as compared with control mice (Figure
S4B) − findings that are in accord with the immunofluor-
escence data.
Thiamet-G (TMG) Enhances Autophagy through an
mTOR-Independent Pathway. Noteworthy is that mTOR is
present in two functionally distinct complexes, namely mTOR
complex 1 (mTORC1) and mTORC2. mTORC1 is well-
known as one of the key negative regulators of autophagy, while
the role of mTORC2 in the direct regulation of autophagy is
still ill-defined.50 Therefore, our study here focused on the
clearly understood pathway involving mTORC1 and do not
rule out involvement of mTORC2. After determining that
OGA inhibition with TMG activates autophagy both in vitro
and in vivo, we set out to study whether TMG stimulates
autophagy through an mTORC1-dependent or mTORC1-
independent pathway. To this end, we analyzed by immunoblot
the phosphorylation status of mTOR as well as mTORC1
substrate proteins p70S6K and 4EBP1. TMG treatment did not
alter phosphorylation of mTOR at Ser2448 and p70S6K at
Thr389 in brains of JNPL3 mice treated with TMG for 36 weeks
(Figure 5A) nor in the brains of CAG-RFP-EGFP-LC3 mice
treated with TMG for 2 weeks (Figure S5). Furthermore, TMG
treatment induced no significant differences relative to controls
in the extent of phosphorylation of either mTOR at Ser2448 or
4EBP1 at Thr37/46 in rat primary cortical neurons (Figure 5B).
Likewise, neither two day nor 15 day treatments with TMG
impacted the extent of phosphorylation of p70S6K at Thr389
and 4EBP1 at Thr37/46 in N2a cells (Figure 5B). Collectively,
these cell and animal data indicated that inhibition of OGA
does not influence the activity of mTORC1 and that TMG
induces autophagy through an mTORC1-independent pathway
in these contexts.
Because AMPK is one of the master regulators of autophagy,
and the O-GlcNAc pathway has been proposed to interact with
AMPK,51 we wondered whether stimulation of autophagy by
OGA inhibition might be mediated through AMPK. We
therefore used immunoblot to analyze the phosphorylation
status of both AMPK and AMPK substrate protein ULK1, the
autophagy-initiating kinase. For neither protein, however, did
we see a significant difference in phosphorylation as assessed in
the brain of JNPL3 mouse, rat primary cortical neurons, and
N2a cells when using site specific antibodies directed toward
Thr172 of AMPK and Ser317 of ULK1 (Figure S6). These data
suggest OGA inhibition does not alter the activity of either
AMPK or ULK1 in neurons or neuronal models.
Tolerability and General Toxicity of Thiamet-G (TMG).
During the preparation of this manuscript, Zhang and co-
workers reported that inhibition of OGA by TMG reduces cell
viability, activates mTOR, and blunts autophagic flux in primary
rat cortical neurons.52 They reported that treating rat primary
cortical neurons with 25 μM TMG for 7 days greatly reduced
cell viability as compared to control cells.52 These surprising
data are not in accord with our work described here, nor with
previous reports from various laboratories that have used TMG.
Indeed, previous studies carried out by independent groups
have shown that systemic administration of TMG for up to 36
weeks does not result in any measurable neurotoxicity in
different mouse models and, moreover, showed reproducible
neuroprotective effects in AD mouse models.22−28 Consistent
with these reports, systemic administration of TMG in mice
showed no obvious signs of toxicity either upon short-term (2
weeks) or long-term (36 weeks) treatments in this study.
Further, we observed no toxicity associated with TMG in in
various immortalized cell lines including N2a, SK-BR-3, MDA-
MB-231, and HEK-293 treated with 25 or 100 μM TMG. In
order to compare our experiments and studies with those of
Zhang and co-workers52 we performed cell viability assays using
a more similar model. We found, however, no difference in the
viability of rat primary cortical neurons treated for 7 days with
vehicle alone or with TMG at concentrations of 25, 100, or 250
μM (Figure S7). Accordingly, our data, alongside that of
others,53 indicate that inhibition of OGA by TMG shows no
neurotoxicity either in vitro or in vivo. We speculate that the
differences between these collective observations and those of
Zhang and co-workers may be attributable to the purity of
TMG, which we prepared and characterized in house using a
range of analytical methods (Figures S8 and S9). Alternatively,
the effects may stem from the primary neurons used in our
study being cocultured with an astrocyte feeder layer, which
leads to more mature neurons with a higher synaptic density, as
compared to Zhang and co-workers who cultured the primary
neurons without an astrocyte feeder layer. Given these
observations, we speculate that the effects of TMG on
autophagy in primary neurons as reported by Zhang and co-
workers may stem from the conditions used, the purity of the
TMG which was not described, or the methods used to assess
autophagic flux. In this regard, it is notable that the Yang group
reported recently that OGA inhibition by TMG stimulates
autophagy in mouse primary hepatocytes54 which though in
different tissue is more consistent with our findings described
here.
Regulation of Autophagy by the O-GlcNAc Pathway.
It is interesting to compare and contrast our observations in
brain with previous studies linking autophagy to perturbations
in cellular O-GlcNAcylation. Our strategy used TMG as a
selective inhibitor of OGA, which hinders the removal of O-
GlcNAc from proteins. Because OGT continues to be active
and add O-GlcNAc onto proteins, the rate of turnover of O-
GlcNAc is decreased with the net result being a global increase
in the levels of O-GlcNAcylated proteins within cells.
Accordingly, TMG treatment is predicted to boost O-
GlcNAcylation of many proteins including autophagy-related
(ATG) proteins as well as other regulators of the autophagy
pathway, which could accordingly alter autophagic flux. Though
no previous studies have examined the effects of increasing O-
GlcNAcylation in mammalian brain tissues, various groups have
enhanced O-GlcNAcylation in other tissues using alternate
strategies including treatment with high concentrations of a
nonselective OGA inhibitor,37 administration of glucosamine,37
or overexpression of OGT.39 In these studies conducted in
murine cardiomyocytes and Drosophila, respectively, the
treatments all led to reduced autophagy.37,39 Decreasing O-
GlcNAcylation by blocking formation of UDP-GlcNAc using
broad spectrum aminotransferase inhibitors,37 knock out of
OGT,38,40 overexpression of OGA,55 or knockdown of OGT38
all enhanced autophagy. More consistent with our study,
reports have found that increasing O-GlcNAcylation by either
knockout of OGA in Caenorhabditis elegans40 or OGA
inhibition using a nonselective OGA inhibitor in neuroblastoma
SH-SY5Y cells56 induces autophagy. Though these studies
employ a range of tools and approaches in different model cells
and organisms, they present a seemingly conflicting set of
observations. We speculate this may be attributed to context
dependency, the complexity of autophagy regulation, and the
pleiotropic effects of O-GlcNAc being an abundant protein
modification found on a diverse set of cellular proteins. Indeed,
autophagy is a complex multistep processes, and can be
regulated at different steps and through different pathways.
There are more than 30 core ATG proteins that together
initiate, promote, and complete autophagosome formation and
degradation, as well as numerous proteins and pathways
dedicated to regulating the process of autophagy.
A series of studies have implicated O-GlcNAcylation in
regulation of autophagy through modification of specific
proteins. Mutating identified O-GlcNAc sites in the autophagy
regulator SNAP-29 was shown to promote autophagy,
suggesting that increased O-GlcNAcylation of SNAP-29 may
function to suppress autophagy.38 In contrast, the O-
GlcNAcylation of the cysteine protease ATG4B was proposed
to increase its proteolytic activity and enhance autophagy56 and
O-GlcNAcylation of ULK1 and ULK2 was proposed to
promote starvation-induced autophagy.54 These specific stud-
ies, alongside those noted above, indicate that the overall
outcome in terms of the downstream effects on autophagic flux
may vary depending on the model and perturbation. Within
specific tissues certain pathways may dominate regulation of
autophagy, accounting for the apparently divergent sets of
observations regarding regulation of autophagy by O-GlcNAc.
These observations collectively suggest that regulation of
autophagy by O-GlcNAc is a complex process that likely is
tissue and environment specific.
■ CONCLUSION
In summary, genetic manipulation of O-GlcNAc levels have
shown varied effects in a range of tissues but limited attention
has been focused on brain, where OGA inhibitors have
demonstrated utility in blocking neurodegeneration. Our data,
in contrast to previous reports in vitro,52 provides compelling
evidence that OGA inhibition enhances autophagy in various
neuronal models to a similar extent as the widely used
autophagy enhancer rapamycin. Unlike rapamycin and its
analogues, which can induce deleterious effects and therefore
have limited potential in chronic indications due to their
blockade of the mTOR pathway,57−60 we find that OGA
inhibitors activated autophagy through an mTOR-independent
pathway as judged by evaluation of downstream markers of
mTORC1 activity. The effects of OGA inhibition on mTORC2
activity are unknown, and cannot be ruled out by these studies.
Importantly, and consistent with previous studies,23,24,28
systemic administration of the OGA inhibitor Thiamet-G
(TMG) at doses of up to 500 mg/kg/day resulted in no
obvious signs of toxicity or behavioral deficits within our mouse
studies noted during routine animal care or within cultured
primary neurons. These findings collectively suggest that OGA
inhibitors are potent and well tolerated compounds that can be
used to perturb autophagy within the brain. Given the
complexity of the pathways regulating and directly driving
autophagy, alongside the large number of proteins known to be
O-GlcNAc-modified within brain, it is likely that OGA
inhibitors act to increase O-GlcNAc on diverse proteins that
contribute to autophagic processes. Understanding these
molecular mechanisms is an area of clear interest and such
work should help uncover more targeted and efficient strategies
to modify autophagy for therapeutic benefit through this
important pathway. While headway has been made in this area
as noted above,38,54,56 a detailed understanding will require
identifying the set of autophagy-related (ATG) proteins and
autophagy regulators modified with O-GlcNAc, determining
which of these are key players in specific tissue types, and
ultimately establishing how O-GlcNAc influences the function
of these key ATG proteins. Regardless of the precise
mechanisms that are operative, our data provide clear support
for TMG, and OGA inhibitors more generally, acting to
enhance autophagy within brain.
Notably, enhancers of autophagy show benefit in a wide
range of neurodegenerative diseases including Parkinson,
Huntington, and Lou Gherig disease.42 Moreover, OGA
inhibitors have been found to offer protection against both
amyloid toxicity in mouse models of disease22,23 as well as in
cellular models of Huntington disease.61 Accordingly, we
envision that TMG and other OGA inhibitors may serve to
protect against a wide range of neurodegenerative diseases
involving proteotoxicity. Given that OGA inhibitors have
recently advanced into early clinical trials, our findings should
stimulate interest in applying such compounds to other
neurodegenerative diseases as well as driving the development
of potential autophagy related biomarkers that could be used to
support advancing OGA inhibitors in clinical studies. Finally,
uncovering specific protein targets within brain that act via O-
GlcNAc to stimulate autophagy in an mTOR-independent
manner may lead to more targeted strategies than global OGA
inhibition.
■ METHODS
Reagents. Bafilomycin A1, rapamycin, and chloroquine were
purchased from Sigma-Aldrich. Thiamet-G (TMG) was synthesized
and characterized as described previously.44
Cell Culture and Treatment. Immortalized cell lines including
N2a, SK-BR-3, MDA-MB-231, and HEK-293 were cultured in
minimum essential medium (MEM) without L-glutamine (Thermo
Fisher Scientific, 11090081) with 2 mM GlutaMAX (Thermo Fisher
Scientific, 35050061), 10% (v/v) fetal bovine serum (FBS, Gibco), and
1% (v/v) penicillin/streptomycin at 37 °C in a water-jacketed,
humidified CO2 (5%) incubator. Cells were treated with TMG at
indicated concentrations for 2 or 15 days. As a positive control, 2.5 μM
rapamycin was added into assigned cell cultures 4 h before collection
of lysates. To inhibit autophagy, cells were incubated with 100 nM
bafilomycin A1 (Sigma) or 25 μM chloroquine for 4 h.
Embryonic day 18 (E18) rat primary hippocampal neurons and
astrocytes were prepared exactly as described previously62 and cultured
in primary neuron growth media (PNGM; Lonza). The astrocyte
feeder layer for the neuronal coculture was generated using neural
progenitor cells as described.63 For immunoblotting experiments, E18
cortical neurons were seeded in 6-well plates at a density of
approximately 3.5 × 105 cells/well and prepared as described.64 All
experiments regarding the preparation of primary neurons and
astrocytes were approved by and followed the guidelines set out by
the Simon Fraser University Animal Care Committee: Protocol #943-
B05. Ten days in vitro (DIV) cortical neurons were exposed to TMG
treatment (100 μM) and rapamycin (0.2 μM). Neuronal cultures were
then incubated for indicated experimental time points. Cell lysates
were collected and subjected to immunoblot analysis.
Antibodies. The following primary antibodies were used in the
Western blotting assays: anti-LC3B (Novus Biologicals, NB100-2220,
1:2000), anti-SQSTM1 (Sigam-Aldrich, P0067, 1:2000), anti-O-
GlcNAc CTD110.6 (Biolegend, 838004, 1:3000), anti-beta-actin
(Santa Cruz Biotechnology, sc-47778, 1:1000), anti-mTOR (Cell
Signaling Technology, 2972S, 1:1000), anti-phospho-mTOR
(Ser2448) (Cell Signaling Technology, 2971S, 1:1000), anti-p70S6K
(Cell Signaling Technology, 2708S, 1:1000), anti-phospho-p70S6K
(Thr389) (Cell Signaling Technology, 9205S, 1:1000), anti-4EBP1
(Cell Signaling Technology, 9452S, 1:1000), anti-phospho-4EBP1
(Thr37/46) (Cell Signaling Technology, 2855S, 1:1000), anti-AMPK
Alpha (Cell Signaling Technology, 2532S, 1:1000), anti-phospho-
AMPK alpha (Thr172) (Cell Signaling Technology, 2535S, 1:1000),
anti-ULK1 (Cell Signaling Technology, 8054S, 1:1000), and anti-
phospho-ULK1 (Ser317) (Cell Signaling Technology, 12753S,
1:1000).
Immunoblot Experiments. Protein samples were separated on 4
15% gradient SDS-PAGE gels (Bio-Rad) and transferred onto PVDF
or nitrocellulose membrane (Bio-Rad). Membranes were blocked for 1
h in PBS-T (PBS, 0.1% Tween 20, pH 7.4) or PBS with 5% bovine
serum albumin (BSA) (Bioshop) at room temperature, and then
incubated with primary antibodies overnight at 4 °C. The following
day, the membrane was rinsed thoroughly with PBS-T two times for 5
min and two times for 10 min. Membranes were then blocked with 3%
BSA in PBS-T for 30 min at room temperature and then incubated
with the IRDye 800CW or IRDye 680LT (Li-Cor) secondary antibody
for 1 h at room temperature in dark followed by washing with PBS-T
twice for 5 min and two times for 10 min. Finally, membranes were
scanned using an Odyssey Infrared Imager (Li-Cor), and images were
analyzed using Odyssey software (Li-Cor).
High-Content Imaging and Analysis. Cells were plated in 10
cm dishes at 10−25% confluency. One plate of cells was administered
with 250 nM or 100 μM TMG immediately after plating. Spent media
was replaced with fresh media containing 250 nM or 100 μM TMG
every 2 days. Another plate of cells was cultured in the same way in
parallel but with no inhibitor as a vehicle control. Thirteen days after
plating, cells in these two 10 cm dishes were trypsinized and counted.
Approximately 5000 cells were then seeded into each well of a 96-well
plate (Corning 4680). Immediately after seeding, a subset of wells with
cells from the vehicle control plate were treated with 250 nM or 100
μM TMG (TMG-S), whereas wells containing cells pretreated with
TMG for 13 days continue to be treated with 250 nM or 100 μM
TMG (TMG-L). Two days later, select wells of the 96-well plate were
incubated with chloroquine and/or rapamycin (positive control) at
indicated concentrations for 4 h. The whole plate of live cells was then
stained with Hoechst 33342 (Thermo Fisher Scientific, H3570) and
CYTO-ID dye (Enzo Life Sciences), which selectively labels
autophagosomes according to the manufacturer’s manual. Live cells
in the plate were automatically imaged using high-content imaging
(ImageXpress Micro XLS, Molecular Devices). Nine different
nonoverlapping fields in each well were automatically selected and
imaged. Images were automatically analyzed using software MetaX-
press (Molecular Devices) to measure the number, area, and CYTO-
ID staining intensity of autophagosomes. Cell lines stably expressing
the fluorescent tandem reporter pHluorin-mKate2-LC3 (from Isei
Tanida; Addgene plasmid # 61458) were cultured, treated and imaged
live in a similar manner as described above. The number of both red
(autolysosome) and yellow puncta (autophagosome) per cell was
automatically quantified using software MetaXpress. Autophagic flux
was presented as the ratio of red/yellow puncta.
Animals. All animal studies described below were approved by the
Simon Fraser University Animal Care Committee. All animals were
administrated TMG at a dose of 500 mg/kg/day. The TMG-treated
group was dosed by including 3.75 mg/mL TMG in the drinking water
bottles. This concentration was based on an average animal weight of
30 g and an average water consumption of 4 mL/day/animal. Both
control and TMG-treated groups were allowed ad libitum access to
food and water. Fourteen 9−12 week old hemizygous female JNPL3
mice (TgN(MAPT)JNPL3HlmcFemale) were obtained from Taconic.
Animals were divided into two groups each containing seven animals,
cohoused in groups of four or three in each cage, and allowed to
acclimatize for 1 week prior to beginning the dosing regimen. JNPL3
mice were dosed with TMG for 36 weeks. Eight 36−40 week old
female 3×Tg-AD “LaFerla mice” (tau (P301L), APP (KM670/
671NL), and PS1 (M146V)) were a kind gift from Charles Krieger’s
lab at Simon Fraser University. These mice were divided into two
groups each containing 4 animals, cohoused in groups of four in each
cage, and allowed to acclimatize for 1 week prior to beginning the
dosing regimen. LaFerla mice were dosed with TMG for 2 weeks.
Fourteen 4−8 week old male RFP-GFP-LC3 mice (C57BL/6-
Tg(CAG-RFP/GFP/Map1lc3b)1Hill/J) were purchased from the
Jackson Laboratory. Animals were divided into two groups each
containing seven animals, cohoused in groups of four or three in each
cage, and allowed to acclimatize for 1 week prior to beginning the
dosing regiment. RFP-GFP-LC3 mice were dosed with TMG for 2
weeks.
Animals were quickly sacrificed with CO2 and perfused trans-
cardially with 60 mL of saline solution. The brain was then quickly
removed and the two hemispheres separated. The left hemisphere was
placed into a solution of 4% paraformaldehyde (PFA). The right
hemisphere was dissected on ice into the cortex, brainstem and
hippocampus regions and quickly frozen in liquid nitrogen. At this
point, all of the samples were relabeled with numbers in order to blind
the investigators carrying out the analysis from the study groups. The
codes were held separately until unblinding at the study end.
Brain tissues were homogenized in six volumes of tissue
homogenization buffer (THB) containing 50 mM Tris-HCl pH 8,
1% (w/v) sodium dodecyl sulfate (SDS), 274 mM NaCl, 5 mM KCl, 2
mM EDTA, 2 mM EGTA, one complete-mini protease inhibitor tablet
(Roche) per 50 mL, 5 mM sodium pyrophosphate, 30 mM β-
glycerophosphate, 30 mM sodium fluoride, and 1 mM phenyl-
methylsulfonyl fluoride (PMSF) and then spun at 13,000g in an
Eppendorf 5417C centrifuge for 20 min in the 4 °C cold-room. The
resulting pellet was then re-extracted with three more volumes of THB
and spun again at 13,000g for 20 min. The supernatants were then
combined and referred to as brain lysates.
Fluorescence Microscopy. Following fixation of the brain in 4%
PFA for 24 h the samples were transferred to 20% (w/v) sucrose
overnight for cryoprotection. Brains were embedded in O.C.T.
(Optimal Cutting Temperature) embedding medium (Sakura Finetek
USA Inc.) and subsequently sectioned in the sagittal plane to generate
30 μm sections using a Leica cryostat. Free floating sections were
permeabilized with 0.1 M PBS (pH 7.4) containing 0.3% Triton X-100
(PBST) for 15 min. After blocking with 10% normal goat serum
(NGS) and 2.5% BSA in PBST for 60 min, sections were incubated
with appropriate primary antibodies at 4 °C for 24 h. After washing
with PBST for 45 min, sections were incubated with appropriate
secondary antibodies conjugated with Alexa 488, Alexa 568, and Alexa
647 (Thermo Fisher Scientific) for 90 min. After 45 min washing, the
sections were mounted on slides (Superfrost/Plus, Fisher), and
coverslipped with Vectashield Mounting Medium with DAPI (H-1200,
Vector Laboratories). Sections examined in parallel but without being
exposed to primary antibody served as experimental controls. Stained
brain sections were analyzed by a Nikon A1R laser scanning confocal
system. For each brain section, images were acquired from three
nonoverlapping fields at each neuroanatomic region including cortex,
hippocampus, and brain stem using 40× or 60× oil-immersion
objectives. Images were then analyzed using software NIS-Elements
AR 3.1 (Nikon) to measure the number of LC3, GFP, and RPF puncta
and quantify immunofluorescent intensity of SQSTM1, AT8, and O-
GlcNAc.
For fluorescent imaging of autophagy in cultured primary
hippocampal neurons, coverslips containing cortical neurons (10
DIV) were subjected to TMG treatment (100 μM) and transfected
with tandem fluorescent reporter pHluorin-mKate2-LC3 using
Endofectin according to the manufacturer’s instructions (GeneCo-
poeia). Neurons were incubated for 24 h after transfection and then
assessed by fluorescence microscopy (72 h exposure to TMG). As a
negative control, bafilomycin A1 (100 nM, Sigma) was added to
assigned coverslips 4 and 1 h before live imaging. Images were
acquired using a Leica DMI6000B inverted epifluorescence micro-
scope using a 63× 1.4 NA oil-immersion objective equipped with a
cooled CCD camera controlled by MetaMorph (Molecular Devices).
Tandem fluorescent reporter expressing neurons were mounted in a
heated chamber (37 °C) and imaged live in both the GFP and RFP
channels. Images of the GFP and RFP channels were merged in
MetaMorph and the number of GFP+ and RFP+ puncta were scored
in the cells treated with the indicated reagents.
Statistical Analysis. Statistical analyses were carried out using
software Graphpad Prism 5.03. Data were analyzed using the unpaired
Student’s t test or one-way analysis of variance (ANOVA) when
comparing more than two values. For all analysis, p < 0.05 was
considered as statically significant. *p < 0.05, **p < 0.01, ***p <
0.001.
Pharmacological inhibition of OGA with different doses
of TMG; other OGA inhibitors enhance autophagy in
cells, OGA inhibitors enhance autophagy in primary rat
astrocytes, TMG increases autophagy in 3xTg-AD mice,
2 week treamtent of mice does not alter mTOR activity
in autophagy reporter mouse brain, OGA inhibition does
not influence activity of AMPK or ULK1 in JNPL3
mouse brain, OGA inhibition with TMG does not affect
viability of rat primary cortical neurons; 1H NMR and
13C NMR spectra; HPLC chromatogram of TMG;
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